title: In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013).
abstract: The in vitro activity of dalbavancin was evaluated against 9303 Staphylococcus aureus and 2670 streptococci, including multidrug-resistant (MDR) isolates, collected from hospitalised patients in Europe and surrounding regions from 2011 to 2013. Dalbavancin recently received approval for the treatment of acute bacterial skin and skin-structure infections by the US Food and Drug Administration (FDA) and the European Medicines Agency. Bacterial identification was confirmed by standard microbiological methods (including MALDI-TOF), and susceptibility testing was performed by reference broth microdilution methods. Dalbavancin susceptibility interpretations followed FDA/EUCAST criteria. Meticillin-resistant S. aureus (MRSA) and streptococci exhibiting resistance to at least three other drug classes were considered as MDR. Dalbavancin was highly active (MIC50/90, 0.06/0.06 mg/L; ≥99.9% susceptible) against MDR and non-MDR MRSA isolates. Vancomycin, daptomycin and linezolid were also active (99.6-100.0% susceptible) against MDR MRSA, however MIC90 values for these drugs were 8- to 16-fold higher than dalbavancin (MIC90 values of 1, 0.5 and 1 mg/L, respectively). All viridans group streptococci (VGS) and β-haemolytic streptococci were susceptible to dalbavancin regardless of resistance phenotype (MIC50/90 values of ≤0.03 mg/L and 0.06 mg/L, respectively). Dalbavancin MIC50/90 results (MIC50/90, ≤0.03/0.06 mg/L) against MDR VGS were at least eight-fold lower than those of vancomycin (MIC50/90, 0.5/1 mg/L), daptomycin (MIC50/90, 0.5/1 mg/L) and linezolid (MIC50/90, 0.5/1 mg/L). Overall, dalbavancin exhibited potent in vitro antibacterial activity against S. aureus and streptococci, including MDR phenotypes. Dalbavancin had the lowest MIC50/90 results against the isolates tested, relative to comparator agents, regardless of resistance phenotypes.
authors.affiliation: JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA. Electronic address: mike-huband@jmilabs.com.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Huband
authors.affiliation: JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA.
authors.forename: Mariana
authors.initials: M
authors.lastname: Castanheira
authors.affiliation: JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA.
authors.forename: David J
authors.initials: DJ
authors.lastname: Farrell
authors.affiliation: JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA.
authors.forename: Robert K
authors.initials: RK
authors.lastname: Flamm
authors.affiliation: JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA.
authors.forename: Ronald N
authors.initials: RN
authors.lastname: Jones
authors.affiliation: JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA.
authors.forename: Helio S
authors.initials: HS
authors.lastname: Sader
authors.affiliation: JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA.
authors.forename: Rodrigo E
authors.initials: RE
authors.lastname: Mendes
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D005060:Europe; D006801:Humans; D008826:Microbial Sensitivity Tests; D013203:Staphylococcal Infections / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D013290:Streptococcal Infections / Q000382:microbiology*; D013291:Streptococcus / Q000187:drug effects* / Q000302:isolation & purification; D017334:Teicoplanin / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D017334:Teicoplanin; C469289:dalbavancin
keywords: Dalbavancin; MDR; MRSA; Multidrug-resistant; Resistance; Surveillance